Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P596: FMT in patients with steroid dependant ulcerative colitis a single centre observational studyECCO '17 Barcelona
Year: 2017
Authors:

Grewal C.S.1, Sood A.2, Mehta V.*2, Kaur D.3

1Dayanand Medical College & Hospital, Gastroenterology, Ludhiana, India 2Dayanand Medical College and Hospital, Ludhiana, India 3Dayanand Medical College and Hospital, Pathology, Ludhiana, India

P597: Ustekinumab use in Crohn's disease: a tertiary centre experienceECCO '17 Barcelona
Year: 2017
Authors:

Greenup A., Rosenfeld G., Bressler B.

University of British Columbia, Gastroenterology, Vancouver, Canada

P598: Mucosal and transmural healing during anti-TNF therapy. Is fecal calprotectin a marker of therapeutic response?ECCO '17 Barcelona
Year: 2017
Authors:

Bertani L.*1, Ceccarelli L.2, de Bortoli N.1, Albano E.1, Tapete G.1, Laino G.1, Mumolo G.2, Ricchiuti A.2, Bellini M.2, Marchi S.1, Costa F.2

1University of Pisa, Department of Translational Research and new Technologies in medicine and surgery, Pisa, Italy 2Pisa University Hospital, Department of Translational Research and new Technologies in medicine and surgery, Pisa, Italy

P599: Home testing for faecal calprotectin: follow-up results from the first UK trialECCO '17 Barcelona
Year: 2017
Authors:

Raker J., Ford C., Pavlidis P., Medcalf L., Choong L.M., Chung-Faye G., Dubois P., Hayee B.

King's College Hospital NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom

P600: Infliximab trough levels for remission induction and long term therapy management of inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Perdigoto D., Portela F., Ferreira M., Mendes S., Freire P., Ferreira M., Lopes S., Tomé L.

Coimbra University Hospital Center, Gastroenterology, Coimbra, Portugal

P601: Can Amitriptylin improve the quality of life in patients with Crohn's disease?ECCO '17 Barcelona
Year: 2017
Authors:

Jigaranu A.O., Dranga M., Gavrilescu O., Popa I., Ungureanu I., Mihai C., Cijevschi-Prelipcean C.

University of Medicine and Pharmacy Gr. T. Popa, IASI, Gastroenterology, Iasi, Romania

P602: Clinical/biochemical predictors of response to anti-TNFa therapies in a tertiary referral centreECCO '17 Barcelona
Year: 2017
Authors:

Tighe D.*1,2, Breslin N.1, Ryan B.1, McNamara D.3

1AMNCH Tallaght/School of Medicine, Trinity College Dublin, Gastroenterology, Dublin, Ireland 2AMNCH Tallaght/School of Medicine TCD, TAGG, Dublin, Ireland 3AMNCH Tallaght/School of Medicine, TCD, TAGG, Dublin, Ireland

P603: Hospitalisation risk and reintervention after ileocolonic resection with anastomosis in patients with Crohn's disease. Results from the PRACTICROHN studyECCO '17 Barcelona
Year: 2017
Authors:

García V.*1, Calvo M.2, Martín Arranz M.D.3, Rivero M.4, Domènech E.5, Barreiro-de Acosta M.6, García Planella E.7, Gutiérrez A.8, Romero C.9, Cea-Calvo L.9, Juliá B.9

1Hospital Universitario Reina Sofia, Unidad Clinica de Aparato Digestivo, Cordoba, Spain 2Servicio de Gastroenterologia Hospital Puerta de Hierro, Madrid, España, Madrid, Spain 3Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain 4Servicio de Gastroenterologia Hospital Marques de Valdecilla, Santander, Spain 5Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain 6Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain 7Unidad de Gastroenterología, Hospital de la Santa Creu y Sant Pau, Barcelona, Spain 8Hospital General Universitario Alicante, Gastroenterology unit, Alicante, Spain 9MSD Spain, Medical Department, Madrid, Spain

P604: Usefulness of stool hemoglobin and fecal calprotectin for detecting of mild to moderate ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Koo J.S., Kim D.J., Lee D.-W., Jeen Y.J.

Korea University College of Medicine, Division of Gastroenterology and Hepatology, Dept. of Internal Medicine, Seoul, South Korea

P605: Rapid detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the reference biologic or the biosimilar CT-P13: performance comparison with ELISAECCO '17 Barcelona
Year: 2017
Authors:

Fiorino G.1, Ametzazurra A.2, Nagore D.*2, Hernández A.M.2, Torres N.2, Radice S.1, Gilardi D.1, Correale C.1, Allocca M.1, Furfaro F.1, Alfieri M.1, Pascual J.2, Recalde X.2, Martínez A.2, Danese S.1,3

1Humanitas Clinical and Research Center, Department of Gastroenterology, Milan, Italy 2Progenika Biopharma SA, R&D Department, Derio, Spain 3Humanitas University, Department of Biomedical Sciences, Milan, Italy

P606: Intestinal fatty acid binding protein parallels temporal changes in Harvey-Bradshaw Index and TNFα in response to infliximab in Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Hellström P.M., Al-Saffar K.A., Tartera Diaz H., Ram G.V., Webb D.-L.

Uppsala University, Department of Medical Sciences, Uppsala, Sweden

P607: Post-operative mortality and predictive factors in a cohort of severe refractory ulcerative colitis patients from the ENEIDA Registry (1989–2013): a multicenter nationwide studyECCO '17 Barcelona
Year: 2017
Authors:

Ordas I.*1, Domenech E.2, Aguas M.3, Fernandez-Bañares F.4, García S.5, Peñalva M.6, Muñoz C.7, García-Sánchez V.8, Llaό J.9, Jiménez C.E.10, Merino O.11, Gomollόn F.12, Piqueras M.13, Vera M.14, Márquez L.15, De Castro M.16, Gutiérrez A.17, Cabriada J.L.18, Alcaide N.19, Calvet X.20, Montoro M.A.21, Arias L.22, Panés J.1, Esteve M.4

1Hospital Clinic Barcelona, Gastroenterology, Barcelona, Spain 2Hospital Universitari Germans Trias i Pujol, Gastroenterology, Barcelona, Spain 3Hospital La Fe, Gastroenterology, Valencia, Spain 4Hospital Universitari Mútua Terrassa, Gastroenterology, Barcelona, Spain 5Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain 6Hospital Universitari Bellvitge, Gastroenterology, Barcelona, Spain 7Hospital de Basurto, Gastroenterology, Bilbao, Spain 8Hospital Reina Sofía, Gastroenterology, Cόrdoba, Spain 9Hospital Sant Pau, Gastroenterology, Barcelona, Spain 10Complejo Hospitalario de Navarra, Gastroenterology, Navarra, Spain 11Hospital de Cruces, Gastroenterology, Bilbao, Spain 12Hospital Lozano Blesa, Gastroenterology, Zaragoza, Spain 13Consorci Sanitari Terrassa, Gastroenterology, Barcelona, Spain 14Hospital Puerta de Hierro, Gastroenterology, Madrid, Spain 15Hospital del Mar, Gastroenterology, Barcelona, Spain 16Complejo Hospitalario de Vigo, Gastroenterology, Vigo, Spain 17Hospital Universitario de Alicante, Gastroenterology, Alicante, Spain 18Hospital de Galdakao, Gastroenterology, Bilbao, Spain 19Hospital Clínico Universitario de Valladolid, Gastroenterology, Valladolid, Spain 20Corporaciό Sanitària Universitària Parc Taulí, Gastroenterology, Barcelona, Spain 21Hospital San Jorge, Gastroenterology, Huesca, Spain 22Hospital General Yagüe, Gastroenterology, Burgos, Spain

P608: New anti-migration extractible metal stents for Crohn's disease strictures: a nationwide GETAID-SFED cohort studyECCO '17 Barcelona
Year: 2017
Authors:

Attar A.*1, Branche J.2, Coron E.3, Privat J.4, Caillo L.5, Chevaux J.-B.6, Vuitton L.7, Amiot A.8, Belkhodja H.9, Buisson A.10, Dray X.11, Jerber L.12, Ponchon T.13, Bouhnik Y.1, Peyrin-Biroulet L.6

1Hopital Beaujon, Gastro-enterologie - MICI- Assistance Nutritive, Clichy la Garenne, France 2Centre Hospitalier Régional Universitaire de Lille, Gastroenterology Department, Lille, France 3Institut des Maladies de l'Appareil Digestif (IMAD), Endoscopie Digestive, Nantes, France 4Centre Hospitalier de Vichy, Service de Gastroentérologie, Vichy, France 5CHU University Hospital, Department of Hepatology and Gastroenterology, Nîmes, France 6CHU Nancy, Department of Gastroenterology and Hepatology, Vandoeuvre-Lès-Nancy, France 7CHU Besancon, Department of Gastroenterology and Hepatology, Besançon, France 8CHU Henri Mondor, Department of Gastroenterology, Creteil, France 9CH Lyon Sud, Gastroenterology Department, Lyon, France 10CHU Estaing, Department of Digestive and Hepatobiliary Medicine, Clermont-Ferrand, France 11APHP St. Antoine Hospital, Department of Gastroenterology and Nutrition, Paris, France 12GETAID, Hospital Saint Louis, Department Of Gastroenterology, Paris, France 13Hospital Edouard Herriot, Department of Gastroenterology and Hepatology, Lyon, France

P609: A treat-to-target approach via a virtual clinic amongst inflammatory bowel disease patients with secondary loss of response to anti-TNF therapy improves clinical outcomesECCO '17 Barcelona
Year: 2017
Authors:

Little R., Taylor K., Friedman A., Headon B., Gibson P., Sparrow M., Ward M.

Alfred Health and Monash University, Gastroenterology, Melbourne, Australia

P610: Efficacy and safety of GLPG1205, a GPR84 antagonist, in ulcerative colitis: multi-centre proof-of-concept studyECCO '17 Barcelona
Year: 2017
Authors:

Vermeire S.*1, Reinisch W.2,3, Wasko-Czopnik D.4, Van Kaem T.5, Desrivot J.6, Vanhoutte F.5, Beetens J.5

1University Hospital Leuven, Gastroenterology, Leuven, Belgium 2McMaster University, Gastroenterology, Hamilton, Canada 3Medical University Vienna, Gastroenterology & Hepatology, Vienna, Austria 4Medical University of Wrocław, Gastroenterology & Hepatology, Wroclaw, Poland 5Galapagos NV, Development, Mechelen, Belgium 6Galapagos SASU, Development, Romainville, France

P611: Relapse risk and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapyECCO '17 Barcelona
Year: 2017
Authors:

Bots S., Kuin S., Ponsioen C., van den Brink G., Löwenberg M., D'Haens G.

Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, Netherlands

P612: Exclusive enteral nutrition in adults with active Crohn's disease is associated with decreased disease activityECCO '17 Barcelona
Year: 2017
Authors:

Pfeffer-Gik T., Yanai H., Godny L., Ron Y., Maharshak N., Dotan I.

Tel Aviv Sourasky Medical Center, IBD Center Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel

P613: Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-alpha inhibitors and conventional immunosuppressantsECCO '17 Barcelona
Year: 2017
Authors:

Macaluso F.S.*1, Maida M.2, Renna S.1, Orlando E.1, Affronti M.1, Sapienza C.1, Dimarco M.1, Orlando R.1, Rizzuto G.1, Cottone M.1, Orlando A.1

1Division of Internal Medicine, “Villa Sofia-Cervello” Hospital, Palermo, Italy 2Gastroenterology and Endoscopy Unit, “Villa Sofia-Cervello” Hospital, Palermo, Italy

P614: Anti-TNFs more frequently stopped due to loss of response in British Asians with Crohn's disease: a single centre retrospective analysisECCO '17 Barcelona
Year: 2017
Authors:

Gadhok R.1, Gordon H.*1, Sebepos-Rogers G.1, Baillie S.1, Akbar S.1, Ahmad O.F.1, Cooper B.1,2, Lindsay J.O.1,3

1Royal London Hospital, Gastroenterology, London, United Kingdom 2Royal London Hospital, London, United Kingdom 3The Blizard Institute, Centre for Immunology, Barts and the London School of Medicine, London, United Kingdom

P615: The unfinished symphony: golimumab is efficient in patients with refractory Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Greener T., Greenberg G., Steinhart H., Silverberg M.

Mount Sinai Hospital, Department of Gastroenterology, Toronto, Canada